secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001125345-25-000111
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CMO Stephen Eck Departs MacroGenics; Frank Perabo Named Interim Lead
--------------------------------------------------------------------

- Stephen Eck, SVP Clinical Development and CMO, to depart MacroGenics effective Dec 31, 2025 by mutual agreement.
- Frank Perabo, VP Clinical Development, will assume interim oversight of clinical development.
- Company has retained executive recruiter to search for a new Chief Medical Officer.
- Dr. Eck joined MacroGenics in July 2020; will receive standard severance per employment agreement upon signing release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000111/0001125345-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000111/mgnx-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer